• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    6/24/21 5:13:50 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TXMD alert in real time by email
    New Drug Application (NDA): 210132
    Company: THERAPEUTICSMD INC
    • Email

    Products on NDA 210132

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    BIJUVA ESTRADIOL; PROGESTERONE 1MG;100MG CAPSULE;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 210132

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    10/28/2018 ORIG-1 Approval Type 4 - New Combination STANDARD Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210132s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210132Orig1s000Ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210132Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    06/22/2021 SUPPL-3 Labeling-Package Insert

    Label is not available on this site.

    06/22/2021 SUPPL-1 Labeling-Package Insert

    Label is not available on this site.

    Labels for NDA 210132

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    10/28/2018 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210132s000lbl.pdf
    Get the next $TXMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXMD

    DatePrice TargetRatingAnalyst
    3/11/2022$3.00 → $2.50Buy
    HC Wainwright & Co.
    11/12/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TXMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

      HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $2.50 from $3.00 previously

      3/11/22 6:31:06 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

      HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $3.00 from $4.00 previously

      11/12/21 6:03:07 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TherapeuticsMD Announces Full Year 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) million, or ($0.74) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.8 million during the year ended Dec

      3/27/25 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Third Quarter 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $547 thousand for the third quarter of 2024, a

      11/12/24 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Second Quarter 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and diluted common share, for the second quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $234 thousand for the second quarter of 2024, a

      8/12/24 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    SEC Filings

    See more

    $TXMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-Q filed by TherapeuticsMD Inc.

      10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)

      5/13/25 4:37:27 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TherapeuticsMD, Inc. (0000025743) (Filer)

      5/13/25 4:15:21 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.

      10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)

      4/30/25 5:00:11 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:38 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:22 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/10/25 4:29:49 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:38 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:22 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/10/25 4:29:49 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care